Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "Th2 cytokines" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
This subset can be further subdivided into Th1 and Th2, and the cytokines they produce are known as Th1-type cytokines and Th2-type cytokines. Th1-type cytokines tend to produce the proinflammatory responses responsible for killing intracellular parasites and for perpetuating autoimmune responses.
Recombinant antibody and antibody fragment
InactiveUS6989145B2Reduce in quantityHigh cytotoxic activitySenses disorderAntibody mimetics/scaffoldsDiseaseDiagnostic agent
A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
Owner:KYOWA HAKKO KIRIN CO LTD
Composition comprising the extract of Actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease
ActiveUS9131722B2Reduce actionTreat and prevent allergic diseaseBiocideSenses disorderFood additiveDisease
The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum and reducing the level of Th2 cytokines and IgE in serum. The present invention also provides a use of above extract for the preparation of pharmaceutical composition. The present invention also provides a health food or food additives, a cosmetic composition, a feed or feed additives comprising above extract for prevention or alleviation of allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum, and reducing the level of Th2 cytokines and IgE in serum.
Owner:VIROMED CO LTD
Method for treating Th2-mediated disease
InactiveUS20050187380A1Reduce in quantityHigh cytotoxic activitySenses disorderAntibody mimetics/scaffoldsDiagnostic agentTh2 cytokines
A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
Owner:KYOWA HAKKO KIRIN CO LTD
Method for treating Th2-mediated disease
InactiveUS7666418B2Reduce in quantityHigh cytotoxic activitySenses disorderAntibody mimetics/scaffoldsDiagnostic agentTh2 cytokines
Owner:KYOWA HAKKO KIRIN CO LTD
DNA vaccination for treatment of autoimmune disease
A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-γ and IL-15, are reduced.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Compositions and methods of use of phorbol esters
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means suchas viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing ThI cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseasesl. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols, therapeutic agents used to treat opportunistic infections due to HIV, or chemotherapeutic agents to yield more effective treatment tools against cytopathic diseases in mammalian subjects.
Owner:BIOSUCCESS BIOTECH CO LTD
Modulation of Th2 lineage commitment by T-bet
InactiveUS20060223116A1Increasing Th cytokine productionEnhances cytokine productionCompounds screening/testingCompound screeningTec kinaseTh2 cytokines
The instant invention is based, at least in part, on the identification of a mechanism by which T-bet directly modulates Th2 cytokine production. The present invention pertains to methods of identifying agents that modulate the Tec kinase-mediated interaction of T-bet with GATA-3, as well as methods of use therefore.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Complex immuno-gene medical composition for inhibiting tumor cells
ActiveUS7323450B2Growth inhibitionRestoring cytotoxicityBiocideSugar derivativesNatural Killer Cell Inhibitory ReceptorsTh2 cytokines
Disclosed is a complex immuno-gene medical composition for activating NK cells to enhance a host immune system. The composition includes a plurality of cytokines, including Th1 and Th2 cytokines. Th2 cytokines antagonize TGF-β inhibiting NK cells to disable the inhibition of the immune system. Th1 cytokines activate NK cells in a host to enhance the host's ability to fight against tumor cells. By use of the complex immuno-gene medical composition, removal of tumor cells is expected.
Owner:NAT TAIWAN UNIV
Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease
InactiveUS20070122508A1Confirm inhibitory effectReduce actionBiocideSenses disorderFood additiveActinidia
The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum and reducing the level of Th2 cytokines and IgE in serum. The present invention also provides a use of above extract for the preparation of pharmaceutical composition. The present invention also provides a health food or food additives, a cosmetic composition, a feed or feed additives comprising above extract for prevention or alleviation of allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum, and reducing the level of Th2 cytokines and IgE in serum.
Owner:HELIXIR
Enhancement of Th2-Dependent and Inflammatory Response
InactiveUS20080213817A1Reduce inflammationReduce diseaseMicrobiological testing/measurementBiological material analysisDiseaseTh2 cytokines
The present invention relates to altering the levels of Th2 cytokine production, and in particular, biasing the cytokine expression profile towards Th2 cytokine production through mitogen-activated protein kinase / ERK kinase kinase 1 (MEKK1), the screening of agents that increase Th2 cytokine production, and the treatment of Th1 associated autoimmune diseases in vivo. In one embodiment, the present invention relates to agents including but not limited to reducing the activity of MEKK1, leading to increased levels of Th2 cytokine production.
Owner:RGT UNIV OF CALIFORNIA
Methods for monoclonal antibody production
InactiveUS20110287454A1Simple methodImmunoglobulins against cytokines/lymphokines/interferonsPeptide preparation methodsPresent methodTh2 cytokines
This invention provides improved methods for production of monoclonal antibodies against a protein of interest. The present methods are based on immunization of an animal with a fusion protein between a protein of interest and a Th2 cytokine such as IL-4, IL-5, IL-13 and IL-31.
Owner:CORNELL UNIVERSITY
Application of bamboo shaving polysaccharides in immunoregulation and tumor resisting
ActiveCN105796587AExcellent function and effectPrevent proliferationOrganic active ingredientsImmunological disordersTh2 cytokinesImmunomodulating Agent
The invention discloses application of bamboo shaving polysaccharides in immunoregulation and tumor resisting. The bamboo shaving polysaccharides have the polysaccharide content not lower than 94.2% and are free of protein; tumors comprise gastric cancer, lung cancer, liver cancer and the like. According to the application, the bamboo shaving polysaccharides (BSPs) are applied to the preparation of anticancer drugs and immunoregulators, and the expression of Th1 / Th2 cytokines is enhanced, so that the bamboo shaving polysaccharides are applied for cancer therapy.
Owner:ZHEJIANG UNIV
Antibodies against inducible TH2 cell factors
A novel TH2 associated gene that is induced by IL-9 has been identified and isolated, thereby providing a therapeutic target for IL-9 mediated diseases such as atopic allergy and asthma-related disorders. The invention also includes methods for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders, methods for diagnosing susceptibility to, and assessing treatment of atopic allergy or asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein. The use of this protein as a therapeutic agent for the treatment of autoimmune diseases is also indicated.
Owner:GENAERA CORP
DNA vaccine for alzheimer's disease
ActiveUS20130122026A1High therapeutic effectHigh affinitySnake antigen ingredientsNervous system antigen ingredientsAmyloid betaTh2 cytokines
Owner:MATSUMOTO
Application of tetrahydrocurcumin in improving allergic asthma
ActiveCN108771664AAlleviate itchingInhibitionKetone active ingredientsRespiratory disorderDiseaseGoblet cell
The invention discloses application of tetrahydrocurcumin in treating allergic asthma. The therapeutic action of the tetrahydrocurcumin (THC) on allergic asthma is firstly found and proved; from the perspective of immunity, the THC can be beneficial to alleviating nose allergy and itching, inhibiting lung eosinophilic granulocyte infiltration, reducing lung goblet cell grume generation, reducing lung collagen deposition, and inhibiting Th2 cell factor production, can provide beneficial information for clinic disease evaluation, and has a favorable application prospect in asthma treatment.
Owner:SUN YAT SEN UNIV
Adjuvant therapy
InactiveUS7214380B1Decrease IgE productionReduce productionBacterial antigen ingredientsPeptide/protein ingredientsAdjuvantTh2 cytokines
Methods are provided for the treatment of allergic and other immune disorders associated with overproduction of Th2 type cytokines by antigen specific T cells. Immunotherapy with adjuvants, as provided in the present invention, greatly inhibits the development of airway hyperreactivity and airway inflammation. Such immunotherapy is shown to reverse ongoing airway disease, and convert allergic inflammatory responses into protective immune responses. Conditions of particular interest include allergic conditions associated with production of Th2 cytokines and / or IgE antibodies, asthma, allergic rhinitis, and anaphylactic reactions. The addition of adjuvant induces a Th1-type immune response and can redirect an established Th2-type response to a Th1-type response for the selected antigen. Preferably, antigen-specific IgE production is reduced without altering the intensity of the antigen-specific proliferative response. One particularly preferred adjuvant for use in accordance with the present invention is a Listeria adjuvant.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Inference sequence capable of inhibiting diabetes mellitus type I CCR5 (CC-chemokine receptor 5) gene expression as well as recombinant vector and application thereof
InactiveCN104059918AAffect secretionBlock processMetabolism disorderGenetic material ingredientsTh2 cytokinesHIV receptor
The invention belongs to the technical field of genetic engineering and specifically relates to an inference sequence capable of inhibiting diabetes mellitus type I specificity-related gene expression as well as a recombinant vector thereof and an application of the recombinant vector in preparing a medicine for treating diabetes mellitus type I. The recombinant vector constructed by the inference sequence is used for transfecting mouse T lymphocytes, so that secretion of Th1 / Th2 cell factors can be affected, and therefore, the recombinant vector plays an important role in insulitis at a prediabetic state, and blocks a process of the diabetes mellitus type I. The invention provides a novel means for treating the diabetes mellitus type I.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Composition Comprising GPCR19 Agonist as an Active Ingredient for Preventing or Treating Allergic Dermatitis
ActiveUS20150290219A1Good effectReduce the amount requiredCosmetic preparationsOrganic active ingredientsDiseaseAllergic dermatitis
The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a G protein-coupled Receptor19 (GPCR19) agonist, specifically sodium taurodeoxycholate (HY2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases. The said pharmaceutical composition shows an excellent efficacy in treating and improving allergic dermatitis compared with the steroid ointments or immunosuppressive ointments currently used. The said pharmaceutical composition reduces the level of serum IgE, which is a major factor causing allergic dermatitis, increases TH1 cytokine alleviating allergic dermatitis and reduces TH2 cytokine that exacerbates allergic dermatitis. The said pharmaceutical composition also reduces infiltration of a mast cell, eosinophil, and neutrophil in dermis and ameliorates clinical symptoms such as erythema, hemorrhage, edema, excoriation, erosion, scaling and dryness. Thus, the said pharmaceutical composition can be used to prevent and treat allergic skin diseases.
Owner:SHAPERON
Complex immuno-gene medical composition for inhibiting tumor cells
ActiveUS20050203037A1Growth inhibitionRestoring cytotocicitySugar derivativesPeptide/protein ingredientsNatural Killer Cell Inhibitory ReceptorsTh2 cytokines
Disclosed is a complex immuno-gene medical composition activating NK cells to enhance host immune system. The composition is usage of a combination of a plurality of cytokines, combined usage of the kinds of Th1 and Th2 cytokines. Th2 cytokine antagonizes TGF-β inhibiting NK cells to disable the inhibition of immune system, and Th1 cytokine activates NK cells in host to enhance the ability fighting against tumor cells. By means of the complex immuno-gene medical composition, removal of tumor cells is expectable.
Owner:NAT TAIWAN UNIV
Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
ActiveUS10098864B2Effectively used for prevention and treatment and alleviation of asthmaReduce airway hyperresponsivenessOrganic active ingredientsAccessory food factorsSide effectTh2 cytokines
Owner:ENZYCHEM LIFESCI CORP +1
Pharmaceutical composition containing wogonin as an active ingredient for preventing or treating asthma
The present invention relates to a pharmaceutical composition for the prevention or treatment of asthma comprising Wogonin as an active ingredient. The Wogonin of the present invention is excellent not only in relieving airway hypersensitivity that causes asthma in vivo, in inhibiting reactive oxygen species generation in the airway, and in inhibiting the infiltration of inflammatory cells in the bronchus, but also in inhibiting the generation of IgE in serum and bronchoalveolar lavage fluid, and in inhibiting the expressions of Th2 cytokines in the lung. Therefore, the Wogonin of the present invention can be effectively used as a composition for the prevention, treatment, or improvement of asthma.
Owner:KOREA RES INST OF BIOSCI & BIOTECH
Relative quantification kit for detecting ribonucleic acid of Thl/Th2 cell factors
InactiveCN102154275AIncrease usageSensitive detectionMicrobiological testing/measurementDNA/RNA fragmentationRoxithromycinRibonucleoside
The invention discloses a reverse transcription primer which can be applied to relative quantification detection of relevant cell factors of a Thl / Th2 cell, a plurality of associatively amplified gene specific primers and a kit. The kit comprises a reagent A: 50muL of 5muM reverse transcription primer, a reagent B: 50muL of 20U / muL M-MuLV reverse transcriptase, a reagent C: 200muL of 5*reverse transcription buffer solution containing 5mM of dNTP (deoxy-ribonucleoside triphosphate) including dATP (deoxyadenosine triphosphate), dCTP (deoxycytidine triphosphate), dGTP (deoxyguanosine triphosphate) and dTTP (deoxythymidine triphosphate)], 250mM of Tris-HCl, 250mM of KCl, 20mM of MgCl2 and 50nM of DTT (dithiothreitol), a reagent D: 2*PCR (Polymerase Chain Reaction) buffer solution, wherein 1mL of buffer solution contains 100 U of taq enzyme, 600nM of ROX (roxithromycin), Green I dye, 2mM of dNTPs (including dATP, dCTP, dGTP and dTTP), 80mM of Tris-HCl, 80mM of KCl, 40mM of (NH4)2SO4 and 6mM of MgSO4, and 24 primer-containing PCR 8 cascade reaction tubes. The entire set of kit provided by the invention can be applied to relative quantification of the cell factors of the Thl / Th2 cell; moreover, relative quantification analysis can be performed on mRNA (messenger ribonucleic acid) fragments of six types of cell factors of different types of T cells, and the immune state of an individual can be estimated according to a result.
Owner:余震 +2
Linear 33 peptide capable of preventing and treating type 1 diabetes and having function of protecting pancreatic beta cells and application of linear 33 peptide
InactiveCN108586619ASuppress immune rebalancingSingle ingredientSenses disorderNervous disorderDiseaseCellular functions
The invention discloses a linear 33 peptide molecule which consists of a B epitope (10 peptide) of human dipeptidyl peptidase 4 and 23 peptide containing a Th2 epitope; serum of an animal immunized by33 peptide contains an antibody which has high price and can be specifically combined with DPP4; the antibody can inhibit the activity of the DPP4 and regulate immune rebalance trending to Th2; the 33 peptide is utilized to carry out subcutaneous immunological control or treat type 1 diabetic NOD mice and treat STZ-induced diabetic mice every 2 weeks, so that blood glucose is significantly controlled or reversed; the blood glucoses of the NOD mice are basically normal, GLP-1 and Th2 cytokines are significantly increased and glucagon and Th1 cytokines are significantly reduced, so that morbidity, death rate, multiple immune balances as well as uric acid, creatinine, blood lipid and oxidative stress indicators are remarkably improved, pancreatic inflammation is relieved, and the ability ofpancreas secreting insulin is significantly strengthened. The 33 peptide as well as vaccines and drugs prepared by using microorganisms, animals, plants and cell expression based on the 33 peptide areof great value in preventing and treating diabetes, especially in type 1 diabetes and complications and other diseases.
Owner:CHINA PHARM UNIV
Function and application of voltage-gated proton channel Hv1 in treating allergic asthma
InactiveCN110547257ARegulates allergic inflammationCompounds screening/testingPreparing sample for investigationAllergic airway inflammationTh2 cytokines
The invention discloses a function of voltage-gated proton channel Hv1 protein in the production of allergic asthma, an established good allergic asthma mouse model, and belongs to the field of medical science. By studying the Hv1 protein, through the comparison with a wild-type C57 (WT) mouse, it is found that the level of allergic airway inflammation in an Hv1 gene knockout mouse (KO) after sensitization and stimulation with ovalbumin (OVA) is significantly higher than that of a control group, that is to say, the Hv1 gene knockout mouse suffers from the allergic asthma. After serum, a bronchoalveolar lavage fluid (BALF) and the pulmonary histopathology are inspected, it is found that Hv1 deficiency significantly promotes the recruitment of OVA-induced inflammatory cells, the level of Th2cytokines of the allergic asthma mouse is increased, and the production of mucus secretion in the allergic asthma mouse is promoted. Through further experiments, it is found that the Hv1 deficiency significantly reduces the expression of NOXs, the results indicate that Hv1 gene knockout increases the prevalence of the allergic asthma by suppressing the yield of ROS. According to the function of the Hv1, the voltage-gated proton channel Hv1 protein can be used for preparing drugs for preventing, alleviating and / or treating the allergic asthma.
Owner:NANKAI UNIV
Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
ActiveUS20160199339A1Effectively used for prevention and treatment and alleviation of asthmaReduce airway hyperresponsivenessOrganic active ingredientsOrganic chemistrySide effectAdditive ingredient
The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.
Owner:ENZYCHEM LIFESCI CORP +1
Application of itaconic acid in preparation of medicine for treating or relieving allergic airway inflammation diseases
PendingCN113209067AGood effectBroaden the types of drugsOrganic active ingredientsRespiratory disorderDiseaseAllergic airway inflammation
Owner:THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
Use of ulinastatin in preparation of drugs for treating multiple sclerosis
InactiveCN105770874ASmall toxicityImprove securityPowder deliveryNervous disorderSide effectTh2 cytokines
The invention belongs to the technical field of medicine and particularly discloses use of ulinastatin in the preparation of drugs for treating multiple sclerosis. It is proved herein that by treating a multiple sclerosis rat (EAE model) with ulinastatin, weight reduction can be significantly reduced for the EAE rat, death rate of the EAE rat can be significantly reduced, onset latency can be significantly delayed, and neural protection can be achieved; in addition, ulinastatin can also increase TGF-beta and IL-10 expression, restore the balance of Th1 / Th2 cell factors and relieve EAE process by reducing IL-2, IFN-gamma and TNF-alpha expression and can accelerate EAE recovery b adjusting apoptosis-promoting Bax and Fas proteins and inhibiting Bcl protein expression. The ulinastatin of the invention has low toxic and side effect, is high in safety, can protect heart, liver, kidney and lung, is low in cost and has a promising development prospect as a drug for treating multiple sclerosis.
Owner:GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Method of treating keloids
PendingUS20220195056A1Avoid typingOrganic active ingredientsImmunoglobulins against cytokines/lymphokines/interferonsTh2 cytokinesKeloid
The present disclosure relates to methods for diagnosing and staging keloids, and to methods of treating keloids using therapeutic compositions that inhibit the Th2 cytokine signaling pathway.
Owner:MT SINAI SCHOOL OF MEDICINE
Composition for preventing, alleviating or treating respiratory diseases, containing siraitia grosvenorii extract as active ingredient
PendingCN112367859AExcellent anti-inflammatory activityExcellent anti-inflammatory activity ratioRespiratory disorderFood ingredient functionsDiseaseWhite blood cell
Owner:KOREA INST OF ORIENTAL MEDICINE
Compounds of phorbol esters and methods of use
The present invention provides methods and compositions comprising crotyl esters or crotyl ester derivatives for the treatment of cytopathic diseases. Cytopathic diseases can be caused by various means, for example, viral infection, such as HIV and AIDS, or the development of neoplastic lesions in mammalian subjects. The methods and compositions of the present invention are effective for inhibiting new HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, downregulating HIV receptors, and increasing Th1 cytokine expression , reducing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant tumor cells, remission induction, remission maintenance, use as a chemotherapeutic agent, and for alleviating the symptoms of cytopathic diseases and the opportunistic infections that accompany these diseases. The present invention provides additional compositions and methods employing crotyl esters or derivatives thereof in combination with at least one additional agent, such as an agent for a course of HAART, a therapeutic agent for treating opportunistic infections due to HIV, or is a chemotherapeutic agent to generate a more effective therapeutic tool against cytopathic diseases in mammalian subjects.
Owner:BIOSUCCESS BIOTECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com